Odanacatib, An Investigational Cathepsin K Inhibitor, Reduced Markers Of Bone Turnover In Women With Breast Cancer And Bone Metastases

July 04th, 2008 | Category: Breast Cancer

Merck & Co., Inc, Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme or MSD, announced results of a new study in which its investigational selective cathepsin K inhibitor odanacatib reduced measures of bone turnover (breakdown and rebuilding of bone) in

women with breast cancer that has spread to the bones (bone metastases). Study results were presented today during an oral session at the VII universal Meeting on Cancer Induced Bone Disease.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Bone Drug Could Help Prevent The Spread Of Breast Cancer
  • Pivotal Phase 3 info Show Denosumab Increased Bone Density all through Skeleton In Non Metastatic Breast Cancer Patients On Adjuvant Inhibitor Therapy
  • Zometa(R) Helps Prevent Bone Loss In Breast Cancer Patients On Aromatase Inhibitors, notes Presented At SABCS
  • Bone Fractures In Many Postmenopausal Women May Be Prevented By Alendronate
  • Preventing Bone Loss After Breast Cancer Treatment Using Osteoporosis Drug

    • No comments yet. Be the first.

    Leave a reply